Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions
Venice Du Pont, Dong Han, Jiani Li, Lauren Rodriguez, Arya Vijjapurapu, Bandita Parhy, Jasmine Moshiri, Kristen Andreatta, Danielle P. Porter, Charlotte Hedskog, John P. Bilello, Hongmei Mo, Caleb Marceau
Elsevier ·
· DOI 10.1016/j.antiviral.2026.106533
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Venice Du Pont, Dong Han, Jiani Li, Lauren Rodriguez, Arya Vijjapurapu, Bandita Parhy, Jasmine Moshiri, Kristen Andreatta, Danielle P. Porter, Charlotte Hedskog, John P. Bilello, Hongmei Mo, & Caleb Marceau Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions. Antiviral Research. https://doi.org/10.1016/j.antiviral.2026.106533
Venice Du Pont, et al. “Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions.” Antiviral Research. doi:10.1016/j.antiviral.2026.106533.
@article{Pont,
title = {Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions},
author = {Pont, Venice Du and Han, Dong and Li, Jiani and Rodriguez, Lauren and Vijjapurapu, Arya and Parhy, Bandita and Moshiri, Jasmine and Andreatta, Kristen and Porter, Danielle P. and Hedskog, Charlotte and Bilello, John P. and Mo, Hongmei and Marceau, Caleb},
journal = {Antiviral Research},
doi = {10.1016/j.antiviral.2026.106533},
url = {https://www.sciencedirect.com/science/article/pii/S0166354226001920?dgcid=rss_sd_all}
}